100 related articles for article (PubMed ID: 12150711)
1. Macroalgal protein hydrolysates from Palmaria palmata influence the 'incretin effect' in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion.
McLaughlin CM; Harnedy-Rothwell PA; Lafferty RA; Sharkey S; Parthsarathy V; Allsopp PJ; McSorley EM; FitzGerald RJ; O'Harte FPM
Eur J Nutr; 2021 Dec; 60(8):4439-4452. PubMed ID: 34081167
[TBL] [Abstract][Full Text] [Related]
2. A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues.
Sicinski KM; Sürmeli D; Du J; Raman VS; Montanari V; Lee M; Harwood BN; Kopin AS; Beinborn M; Kumar K
J Med Chem; 2024 Mar; 67(6):4998-5010. PubMed ID: 38458970
[TBL] [Abstract][Full Text] [Related]
3. Glucose-dependent insulinotropic polypeptide deficiency reduced fat accumulation and insulin resistance, but deteriorated bone loss in ovariectomized mice.
Shimazu-Kuwahara S; Kanemaru Y; Harada N; Ikeguchi E; Ueda Y; Yamane S; Murata Y; Yasoda A; Kieffer TJ; Inagaki N
J Diabetes Investig; 2019 Jul; 10(4):909-914. PubMed ID: 30451382
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes--a role for the transcription factor NFAT and phosphodiesterase 3B.
Omar B; Banke E; Guirguis E; Åkesson L; Manganiello V; Lyssenko V; Groop L; Gomez MF; Degerman E
Biochem Biophys Res Commun; 2012 Sep; 425(4):812-7. PubMed ID: 22892131
[TBL] [Abstract][Full Text] [Related]
5. GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomics.
Masaki T; Kodera Y; Terasaki M; Fujimoto K; Hirano T; Shichiri M
Sci Rep; 2021 Jul; 11(1):14470. PubMed ID: 34262109
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Antidiabetic and Insulin Releasing Effects of
Ansari P; Flatt PR; Harriott P; Abdel-Wahab YHA
Plants (Basel); 2020 Oct; 9(10):. PubMed ID: 33053901
[No Abstract] [Full Text] [Related]
7. β-Catenin mediates glucose-dependent insulinotropic polypeptide increases in lysyl oxidase expression in osteoblasts.
Daley EJ; Trackman PC
Bone Rep; 2021 Jun; 14():101063. PubMed ID: 33981809
[TBL] [Abstract][Full Text] [Related]
8. Identification of Multiple Pancreatic and Extra-Pancreatic Pathways Underlying the Glucose-Lowering Actions of
Ansari P; Flatt PR; Harriott P; Hannan JMA; Abdel-Wahab YHA
Plants (Basel); 2021 Jun; 10(6):. PubMed ID: 34208010
[No Abstract] [Full Text] [Related]
9. Impaired Gastric Hormone Regulation of Osteoblasts and Lysyl Oxidase Drives Bone Disease in Diabetes Mellitus.
Daley EJ; Pajevic PD; Roy S; Trackman PC
JBMR Plus; 2019 Oct; 3(10):e10212. PubMed ID: 31687648
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of targeting bone-specific GIP receptor in ovariectomy-induced bone loss.
Mabilleau G; Gobron B; Mieczkowska A; Perrot R; Chappard D
J Endocrinol; 2018 Nov; 239(2):215-227. PubMed ID: 30121578
[TBL] [Abstract][Full Text] [Related]
11. Gut hormone polyagonists for the treatment of type 2 diabetes.
Brandt SJ; Götz A; Tschöp MH; Müller TD
Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
[TBL] [Abstract][Full Text] [Related]
12. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
Mohammad S; Patel RT; Bruno J; Panhwar MS; Wen J; McGraw TE
Mol Cell Biol; 2014 Oct; 34(19):3618-29. PubMed ID: 25047836
[TBL] [Abstract][Full Text] [Related]
13. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
Gault VA; O'Harte FP; Harriott P; Flatt PR
Metabolism; 2003 Jun; 52(6):679-87. PubMed ID: 12800091
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
15. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
[TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.
Gault VA; Flatt PR; O'Harte FP
Biochem Biophys Res Commun; 2003 Aug; 308(2):207-13. PubMed ID: 12901855
[TBL] [Abstract][Full Text] [Related]
17. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
Gault VA; Flatt PR; Bailey CJ; Harriott P; Greer B; Mooney MH; O'harte FP
Biochem J; 2002 Nov; 367(Pt 3):913-20. PubMed ID: 12150711
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
